此外，微创机器人此前宣布拟配售3470万股。配售事项已于2024年12月10日完成。配售所得款项净额约2.66亿港元，70%用于本集团核心业务的发展，包括就产品表现提升及优化升级进行研发以及集团产品海内外商业化；30%用于补充营运资金及一般公司用途。MEDBOT-B (02252) rises over 6%, as of this report, it has increased by 6.31%, priced at 10.78 Hong Kong dollars, with a transaction volume of 0.211 billion Hong Kong dollars.
According to Zhitong Finance APP, MEDBOT-B (02252) rises over 6%, as of this report, it has increased by 6.31%, priced at 10.78 Hong Kong dollars, with a transaction volume of 0.211 billion Hong Kong dollars.
In news, the Chinese National Government Procurement Network recently announced the results of centralized procurement bids for coronary intervention Control System from five hospitals, including Zhongshan Hospital affiliated to Fudan University, with R-One successfully winning the bid, priced at 15.2 million yuan per unit, totaling 76 million yuan. It is reported that R-ONE is a vascular intervention surgical robot introduced by the joint venture formed by Shanghai MEDBOT and France's Robocath S.A.S. MEDBOT previously disclosed in its mid-term report that the R-ONE vascular intervention robot, which is laid out in the pan-vascular field through international cooperation, will accelerate inpatient promotion after receiving NMPA approval in December 2023, has already accumulated multiple sales Orders, and the first two commercial installations in the Chinese market have been achieved during the reporting period.
Additionally, MEDBOT previously announced plans to place 34.7 million shares. The placement has been completed on December 10, 2024. The net proceeds from the placement are approximately 0.266 billion Hong Kong dollars, with 70% used for the development of the Group's core Business, including research and development for product performance enhancement and optimization upgrades as well as commercialization of Group products both domestically and internationally; 30% will be used to supplement working capital and for general corporate purposes.
